The U.S. Food and Drug Administration (FDA) approved the first-ever respiratory syncytial virus (RSV) vaccine for use in adults aged 60 and over on Wednesday. The approval of its drug Arexvy is a major victory for British pharmaceutical giant GlaxoSmithKline ...